Pharmacokinetics of once-a-month injectable contraceptives.
The addition of a short- or medium-acting estrogen ester to the long-acting progestins depot-medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN) to produce "combined" injectable formulations has proved a successful strategy in the development of once-a-month injectable contraceptives. Recent clinical pharmacokinetic studies undertaken on once-a-month injectable contraceptives in various WHO Collaborating Centers have guided the selection of the estrogen-progestogen combinations, ratios and dose schedules. At least three combined once-a-month injectable preparations exhibit acceptable pharmacokinetic and pharmacodynamic profiles; however, further improvement in the design of optimal estrogen/progestin injectables are expected during this decade.
Garza-Flores
J
J
Department of Reproductive Biology, National Institute of Nutrition S. Zubiran, Mexico City, Mexico.
D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D004967:Estrogens / Q000008:administration & dosage / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D011372:Progestins / Q000008:administration & dosage / Q000493:pharmacokinetics
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D004967:Estrogens; D011372:Progestins